Reaction: Enzalutamide to 1 product

Reaction
Enzalutamide
DB08899
M6 enzalutamide
DBMET03549
Reaction type
hydroxylation
Direction
Major circulating metabolite?
No
Spontaneous?
No
Activity
unknown
References
  1. Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA, van Oort IM, Burger DM, van Erp NP: Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. Clin Pharmacokinet. 2016 Nov;55(11):1369-1380. doi: 10.1007/s40262-016-0403-6. [Article]
  2. Gibbons JA, Ouatas T, Krauwinkel W, Ohtsu Y, van der Walt JS, Beddo V, de Vries M, Mordenti J: Clinical Pharmacokinetic Studies of Enzalutamide. Clin Pharmacokinet. 2015 Oct;54(10):1043-55. doi: 10.1007/s40262-015-0271-5. [Article]
  3. FDA Approved Drug Products: Xtandi (enzalutamide) capsules/tablets for oral use (September 2022) [Link]
Comments
Not Available
Enzymes
EnzymeKmVmaxRole
Cytochrome P450 3A4Not AvailableNot Availableconfirmed
Cytochrome P450 2C8Not AvailableNot Availableconfirmed